Mobile

A phase 2, randomized, open-label, parallel, study with sotatercept in patients with anemia and low or intermediate-1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leukemi...

Update Il y a 4 ans
Reference: EUCTR2012-002601-22

A phase 2, randomized, open-label, parallel, study with sotatercept in patients with anemia and low or intermediate-1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leukemia

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this study is to determine a safe, tolerable and effective dose of sotatercept that results in the greatest frequency of erythroid hematological improvement (HI-E) in patients with anemia and low- or intermediate-1 risk MDS.

Inclusion criteria

  • Anemia and low or intermediate-1 risk myelodysplastic syndromes, or non-proliferative chronic myelomonocytic leukemia (CMML)

Links